Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

Author(s):

Joeseph Renzulli, MD,Ganesh V. Raj, MD, PhD

Key Takeaways

Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide.
These combination therapies improve overall survival and progression-free survival in mCSPC patients.
Treatment choice is influenced by patient comorbidities, disease burden, and patient preference, necessitating individualized treatment plans.

Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Emerging Trends and Rising Prevalence of mCSPC

EP: 2.Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP: 3.Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP: 4.Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP: 5.Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

Now Viewing

EP: 6.Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP: 7.Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

Video content above is prompted by the following:

What are the guideline-recommended treatment options for patients with mCSPC (“castration-naive” CSPC)?

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!